COSCIENS Biopharma Inc (CSCI) - חוב להון עצמי

COSCIENS Biopharma Inc. (CSCI) is currently transforming its model, replacing legacy assets with the development of an advanced pipeline of orphan drugs. The market capitalization trend reflects a total debt-to-equity ratio of 0.32, complementing an expansion strategy in Latin America and Canada through license acquisitions. The business relies on a team of independent scientists attracted by flexible management and equity incentives.

This indicator is calculated as the ratio of total debt obligations to equity, measuring the business's degree of reliance on borrowed funds. For COSCIENS Biopharma Inc. (CSCI), which possesses pricing power in neurology, analyzing the total liability-to-equity ratio allows for an assessment of how effectively the high margins of orphan drugs cover the debt load.